Theseus Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Theseus Pharmaceuticals (NASDAQ: THRX), a clinical-stage biopharmaceutical company dedicated to cancer treatment, will virtually participate in the SVB Securities Global Biopharma Conference from February 14-16, 2023. The fireside chat is scheduled for February 16 at 10:40 AM ET. Investors can access a live webcast on their investor relations website, which will be available for 30 days post-event. Theseus focuses on developing targeted therapies for cancer, including the lead candidate THE-630 for advanced gastrointestinal stromal tumors.

CAMBRIDGE, Mass., Feb. 7, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the Company will participate virtually in the SVB Securities Global Biopharma Conference, taking place February 14-16, 2023.

Details:
Event: SVB Securities Global Biopharma Conference
Fireside Chat Date / Time: Thursday, February 16^th at 10:40am ET

A live webcast will be available in the Events section of the company's investor relations website at ir.theseusrx.com and archived for 30 days following the presentation.

About Theseus Pharmaceuticals, Inc.

Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all classes of cancer-causing and resistance mutations that lead to clinically relevant variants in a particular protein in a given type of cancer. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing THE-349, a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC), and a pan-variant BCR-ABL inhibitor for the treatment of relapsed/refractory chronic myeloid leukemia (CML) and newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). For more information, visit www.theseusrx.com.

Media Contact
Christen Baglaneas
Director, Corporate Communications & Investor Relations
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com

Investor Contact
Josh Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com

View original content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-in-the-svb-securities-global-biopharma-conference-301739841.html

SOURCE Theseus Pharmaceuticals

FAQ

What is the date of Theseus Pharmaceuticals' participation in the SVB Securities Global Biopharma Conference?

Theseus Pharmaceuticals is participating in the SVB Securities Global Biopharma Conference from February 14-16, 2023.

When will Theseus Pharmaceuticals' fireside chat take place?

Theseus Pharmaceuticals' fireside chat will occur on February 16, 2023, at 10:40 AM ET.

How can I access the webcast for Theseus Pharmaceuticals' conference participation?

You can access the live webcast on the investor relations section of the Theseus Pharmaceuticals website.

What is the focus of Theseus Pharmaceuticals?

Theseus Pharmaceuticals focuses on developing transformative targeted therapies for cancer patients.

What is the lead product candidate of Theseus Pharmaceuticals?

The lead product candidate of Theseus Pharmaceuticals is THE-630, a pan-variant KIT inhibitor.